I write content for the people building psychedelic-assisted therapy into something real — the clinics running ketamine programs, the companies developing the next generation of molecules, the researchers pushing the science forward.
Web copythat turns your practice into a place people trust
Blog contentthat explains the science without dumbing it down — or dressing it up
Case studies and white papersthat prove your work matters
AEO and SEO strategyso your content shows up in search engines and AI answers
Who It's For
01Therapists and clinicsoffering ketamine, psilocybin, or MDMA-assisted therapy
02B2B companiesbuilding tools, platforms, or services for the PAT space
03Researcherswho need someone to translate their work for the people who need to read it
04Investors and advocateswho want credible, compelling stories about where this field is going
Why Me
Most copywriters in the psychedelic space fall into one of two camps: heavy on the mystical framing, or clinical to the point of lifeless. Neither serves your audience.
I'm the third option.
I've spent years studying this space — the legislation, the research, the companies, the people. I hold a KCS v6 Fundamentals certification. I've published work on AEO (how content shows up in AI-generated answers), built a chatbot case study from scratch, and spent 11+ years at Apple and CrashPlan learning how to translate complex technology into language people can actually use.
I'm not a scientist. I'm not a therapist. I'm a writer who did the reading — and can break it down for the people who need to understand it.
That's the whole pitch.
I'm not a scientist. I'm not a therapist. I'm a writer who did the reading.
Experience
For 11+ years at Apple and CrashPlan, I did the same thing I do now: took something complicated, made it less intimidating, and explained what came next.
Apple
7+ years
CrashPlan
4 years
KCS v6 Fundamentals
Certified by the Consortium for Service InnovationCreating, reusing, and improving useful knowledge.
AI is moving into psychedelic-assisted therapy — drug discovery, patient screening, session support. Some of it is real. Some is still promise. Here's what's actually happening right now.
Two prominent psychedelic companies rebranded in 2026 — leading with the language of pharma and psychiatry instead. Here's why the language battle matters for funding, prescribing, and the future of this field.